Andrew Galazka

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis.

Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis.

Journal: Clinical and translational science

Published: December 20, 2024

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.

Journal: Neurology and therapy

Published: July 26, 2023

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.

Journal: Neurodegenerative disease management

Published: August 26, 2022

The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.

The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.

Journal: Neurodegenerative disease management

Published: August 03, 2022

Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.

Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.

Journal: Clinical pharmacokinetics

Published: November 07, 2021

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.

Journal: Frontiers in immunology

Published: August 23, 2021

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine.

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine.

Journal: Clinical pharmacokinetics

Published: July 28, 2021

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 10, 2021

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.

Journal: Multiple sclerosis and related disorders

Published: March 12, 2021

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.

Journal: Current medical research and opinion

Published: December 17, 2020

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

Journal: Drugs

Published: November 28, 2020

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: September 28, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026